Navigation Links
PharmaNet and Anapharm Europe Formally End Joint Venture
Date:1/26/2011

BARCELONA, Spain, Jan. 26, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc. and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

In conjunction with the termination of this relationship, Dr. Maria Cruz Caturla, Anapharm Europe's majority shareholder, has purchased PharmaNet's minority ownership interest, thus becoming the sole owner of the company.

The companies will independently continue to invest in, and provide to clients, bioanalytical services in their respective laboratory facilities. Additionally, to the extent necessary, the companies will provide coordinated support for those client projects undertaken jointly during the term of the joint venture.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

About Anapharm Europe, S.L.

Anapharm Europe is a leading provider of bioanalytical services for the pharmaceutical, biopharmaceutical and generic firms, working with the most prestigious clinical pharmacology units in Spain, the rest of Europe, and around the world. Located in Barcelona, Spain, its GLP-certified laboratory has high-capacity, state-of-the-art equipment and
'/>"/>

SOURCE PharmaNet Development Group, Inc.; Anapharm Europe, S.L.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
2. PharmaNets Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics
3. PharmaNet Launches New Brand Identity at Upcoming Industry Conferences
4. PharmaNet Development Group Announces Observational Research Survey
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
8. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
9. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
10. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
11. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Breckenridge Pharmaceutical, Inc. announced today that it ... Pvt. Ltd. ( Hyderabad, India ) under ... ANDAs.  Under the terms of the agreement, MSN will ... for the U.S. market, and Breckenridge will market and ... have agreed to develop an oral antibiotic with current ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... United States will increase to a value ... primarily driven by expansion in the large direct energy ... will be increasingly adopted due to the advantages they ... Other key findings from Decision Resources Group,s coverage of ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... DURATION-1 Data Presented at the 68th Annual Scientific Sessions of the ... American Diabetes ... AMLN ), Eli Lilly and Company (NYSE: LLY ), and ... that compared the,efficacy of exenatide once weekly, a long-acting release formulation ...
... Indicate GlycoMark May Be a More Effective Monitor Than, ... ... Populations, SAN FRANCISCO, June 7 GlycoMark, Inc. ... that the GlycoMark,blood test is a better reflection of ...
Cached Medicine Technology:Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 2Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 3Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 4Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 5Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 6Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 7Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 8DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 2DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 3
(Date:12/21/2014)... By Dennis Thompson ... -- Former tobacco smokers find e-cigarettes less addictive than traditional ... e-cigarettes as often as they did regular cigarettes, thousands of ... to feel impulsive and irritable over their need to smoke, ... clear. The score was significantly less for e-cig use than ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... CA (PRWEB) December 21, 2014 Over ... resolved performance issues in hundreds of emergency departments across ... satisfaction. Its findings have been translated into an innovative ... leaders to correct deficiencies and enhance the patient experience. ... outsourced emergency physician staffing and management services for hospitals, ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... Lvov, a chemistry professor in Louisiana Techs Institute for ... the Year, beating candidates from Princeton University and companies ... in the journals January 2008 issue. , Lvov received ... cancer drugs. His research pioneers drug reformulation through polyelectrolyte ...
... YORK, Dec. 5 At a briefing ... vice president -- DuPont,Performance Materials, discussed the ... $6 billion in annual sales, the DuPont,Performance ... value-added applications development for the global,packaging, transportation, ...
... event of its kind in the country, provides ... healing and other resources, ... District, is hosting the fourth,Breaking The Silence 2007: A Summit on ... - 8 p.m. and Saturday,December 8, 8 a.m. - 3 p.m. ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), announced today ... Jane H. Hsiao, Ph.D., have resigned from,the Company,s ... reasons. Dr. Hsiao was a member of the ... Protalix BioTherapeutics, Inc., Protalix is a biopharmaceutical ...
... As companies transform their,call centers into service-to-sales operations, ... while maintaining a customer service,function. Because they play ... is one of the key factors behind a ... leaders recommend reducing spans of control by as,much ...
... Resources to Coordinate Care, NEWTON, Mass., Dec. ... as a major cause of stress and functional ... in America are in a,silent crisis; overwhelmed by ... or elderly family member. These families face a,multitude ...
Cached Medicine News:Health News:Louisiana Tech professor is Small Times' Innovator of the Year 2Health News:DuPont Group Vice President Briefs Investors on Performance Materials Segment 2Health News:Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes' Behavioral Mental Health Summit 2Health News:Protalix BioTherapeutics Announces Resignation of Board Members 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2Health News:Family Caregivers in Crisis Have New Hope 2
Fine 3.0 mm platformed angled 60 degrees 10 mm from angle to tip. Serrated handle with dull finish....
Tennant straight tying forceps, 6.0 mm tying platforms, with pin, extra delicate smooth jaws....
Sinskey tying forceps, straight, fine, 7 mm tying platforms....
O'Gawa-Castroviejo tying forceps, straight shafts, 6 mm tying platforms, wide handle....
Medicine Products: